Log in

Relevant bibliographies by topics / Anti-Sars-Cov-2 / Journal articles

To see the other types of publications on this topic, follow the link: Anti-Sars-Cov-2.

Journal articles on the topic 'Anti-Sars-Cov-2'

Author: Grafiati

Published: 25 January 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anti-Sars-Cov-2.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Lippi, Giuseppe, Gian Luca Salvagno, Brandon M. Henry, Laura Pighi, Simone De Nitto, and Gianluca Gianfilippi. "Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination." Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 3, no. 1 (2021): 39–43. http://dx.doi.org/10.1515/almed-2021-0086.

Full text

Abstract:

Abstract Objectives This article aims to summarize the 6-month variation of a vast array of anti-SARS-CoV-2 antibodies in recipients of BNT162b2 mRNA-based vaccination. Methods The study population consisted of 84 baseline SARS-CoV-2 seronegative healthcare employees (median age 45 years, 53.6% females), receiving mRNA-based BNT162b2 primary vaccination cycle. Blood was collected before the first and second BNT162b2 vaccine doses, as well as 1, 3 and 6 months afterwards. The serum titers of the following anti-SARS-CoV-2 antibodies were assayed: total anti-RBD (receptor binding domain), anti-sp

APA, Harvard, Vancouver, ISO, and other styles

2

Geanes, Eric S., and Todd Bradley. "Differences between autoantibodies induced by SARS-CoV-2 infection and Pfizer-BioNTech SARS-CoV-2 vaccination." Journal of Immunology 208, no. 1_Supplement (2022): 65.15. http://dx.doi.org/10.4049/jimmunol.208.supp.65.15.

Full text

Abstract:

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can induce severe disease and lead to hospitalization and/or death in some subpopulations of patients. The underlying mechanisms of disease severity between individuals remain unclear. Recently, autoantibodies have been detected after severe SARS-CoV-2 infection, including anti-idiotypic IgM antibodies targeting ACE2, the receptor for SARS-CoV-2. In this study, we examined autoantibody differences within hospitalized patients with severe SARS-CoV-2 infection, individuals with previous SARS-CoV-2 infection (seroposi

APA, Harvard, Vancouver, ISO, and other styles

3

Furukawa, Hiroshi, Shomi Oka, Takashi Higuchi, et al. "Detection of Anti-SARS-CoV-2 Nucleocapsid and Spike Antibodies in Patients with Coronavirus Disease 2019 in Japan." Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 16 (January 2022): 117954842210754. http://dx.doi.org/10.1177/11795484221075492.

Full text

Abstract:

OBJECTIVES Coronavirus Disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Serological testing for anti-SARS-CoV-2 nucleocapsid (N) antibodies (Abs) and anti-SARS-CoV-2 spike (S) Abs is performed to detect prior COVID-19 infection. It is still controversial which antibodies are the most sensitive and specific, and which can be detected earliest after infection. Here, we evaluated the results of serological tests of anti-SARS-CoV-2 N and S Abs in Japan. METHODS Symptomatic COVID-19 patients (n = 84) and control patients with rheumatoid arthriti

APA, Harvard, Vancouver, ISO, and other styles

4

Siddi, Mariana, Paolo Molinari, Carlo Maria Alfieri, et al. "Prevalence and Risk Factors for Anti-SARS-CoV-2 Antibody in Chronic Kidney Disease (Dialysis Independent and Not)." Pathogens 11, no. 5 (2022): 572. http://dx.doi.org/10.3390/pathogens11050572.

Full text

Abstract:

Background: The evidence in the medical literature regarding the prevalence of antibody towards SARS-CoV-2 in patients with chronic kidney disease is limited, particularly among those at the pre-dialysis stage. Aim: We have prospectively performed a cohort study at a third-level university hospital to evaluate frequency and risk factors for anti-SARS-CoV-2-positive serology among chronic kidney disease patients. Methods: We have tested a cohort of consecutive outpatients with chronic kidney disease on regular follow-up at a major metropolitan hospital, during the SARS-CoV-2 outbreak in Italy.

APA, Harvard, Vancouver, ISO, and other styles

5

Herroelen, Pauline H., Geert A. Martens, Dieter De Smet, Koen Swaerts, and An-Sofie Decavele. "Humoral Immune Response to SARS-CoV-2." American Journal of Clinical Pathology 154, no. 5 (2020): 610–19. http://dx.doi.org/10.1093/ajcp/aqaa140.

Full text

Abstract:

Abstract Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests are clinically useful to document prior SARS-CoV-2 infections. Data are urgently needed to select assays with optimal sensitivity at acceptable specificity for antibody detection. Methods A comparative evaluation was performed of 7 commercial SARS-CoV-2 serology assays on 171 sera from 135 subjects with polymerase chain reaction–confirmed SARS-CoV-2 infection (71 hospitalized patients and 64 paucisymptomatic individuals). Kinetics of IgA/IgM/IgG seroconversion to viral N and S protein epitopes were

APA, Harvard, Vancouver, ISO, and other styles

6

Germer, Matthias, Viola Marschall, Veit Braun, Jörg Schüttrumpf, and Matthias Germer. "Rising anti-SARS-CoV-2 titer in a human immunoglobulin preparation." International Journal of Blood Transfusion and Immunohematology 13, no. 1 (2023): 1–8. http://dx.doi.org/10.5348/100076z02ch2023ra.

Full text

Abstract:

Aims: To assess potential changes of pharmacological activities of a novel normal immunoglobulin for intravenous administration from pooled normal plasma (IVIG). Methods: We assessed the impact of the SARS-CoV-2 pandemic on the level and activity of pathogen-specific antibodies in IVIG batches produced before and during the pandemic. Antibody levels were determined by immunoassays. The functional activity of SARS-CoV-2 antibodies was determined by in vitro neutralization. Results: In the IVIG, the antibody titer against bacteria, different viruses and a fungus were found to be in a defined ran

APA, Harvard, Vancouver, ISO, and other styles

7

Häusler, Sebastian, Marco Weigl, Andreas Ambrosch, Rudolf Gruber, Birgit Seelbach-Göbel, and Sara Fill Malfertheiner. "Peripartal anti-SARS-CoV-2-IgA/IgG in asymptomatic pregnant women during regional SARS-CoV-2-outbreak." Journal of Perinatal Medicine 49, no. 6 (2021): 709–16. http://dx.doi.org/10.1515/jpm-2021-0001.

Full text

Abstract:

Abstract Objectives The Severe Acute Respiratory Distress Corona Virus 2 (SARS-CoV-2) pandemic poses special challenges for the society and especially the medical staff. Even if a rather mild course is assumed among pregnant women the measures to prevent transmission of the infection are of outstanding importance. Methods To screen asymptomatic pregnant women during admission to our university maternal hospital we focused on anti-SARS-CoV-2-specific IgG and IgA antibody responses. Hundred and fifty one women admitted to the hospital for childbirth or caesarean delivery were included. In case o

APA, Harvard, Vancouver, ISO, and other styles

8

Kittel, Maximilian, Romy Eichner, Sihem Aida, et al. "Results of a European-Wide External Quality Assessment (EQA) Scheme for Serological Detection of Anti-SARS-CoV-2 (CoVimm)—Pitfalls of Routine Application." Viruses 14, no. 8 (2022): 1662. http://dx.doi.org/10.3390/v14081662.

Full text

Abstract:

Background: During the last two years, a variety of assays for the serological detection of antibodies to the new SARS-CoV-2 virus have been launched and used as part of standard care in many laboratories. The pace with which these tests have been introduced into routine care emphasizes the importance of quality measures for analytical methods, particularly with regard to the implications of results for clinical and epidemiologic decisions. Accuracy, reliability and comparability of analytical test results are thus essential, and here external quality assessment (EQA) is the most important qua

APA, Harvard, Vancouver, ISO, and other styles

9

Brice, David, and Maureen A. McGargill. "Coronavirus spike protein vaccination history affects SARS-CoV-2 receptor-binding domain-specific memory response in a mouse model." Journal of Immunology 210, no. 1_Supplement (2023): 235.19. http://dx.doi.org/10.4049/jimmunol.210.supp.235.19.

Full text

Abstract:

Abstract Background: Previous exposure to human common cold coronaviruses (hCCCoVs) has been shown to affect immune responses to SARS-CoV-2. Since most humans have been infected with different hCCoVs throughout their lives, determining exactly how previous immunity to hCCoVs affects anti-SARS-CoV-2 responses, especially to the Spike (S) protein and its receptor-binding domain (RBD), has proven difficult. We, therefore, used a mouse model to investigate how exposure to different coronavirus S alters the immune response to SARS-CoV-2 S vaccination. Methods: C57BL/6 mice were vaccinated intramusc

APA, Harvard, Vancouver, ISO, and other styles

10

Notrisia Rachmayanti, Bastiana Bermawi, and Diyan Wahyu Kurniasari. "Pemeriksaan Skrining Covid-19 Kepada Pegawai Laboratorium Rumah Sakit Islam Surabaya Jemursari di Masa Pandemi." SEMINAR NASIONAL PENGABDIAN KEPADA MASYARAKAT 2021 1, no. 1 (2022): 1094–99. http://dx.doi.org/10.33086/snpm.v1i1.925.

Full text

Abstract:

COVID-19 telah menjadi pandemi sejak Januari 2020. COVID-19 disebabkan oleh SARS-CoV 2 yang menyebar melalui droplet dan airborne sehingga petugas kesehatan rentan tertular. RSI Surabaya Jemursari telah merawat pasien COVID-19 dan melakukan pemeriksaan PCR SARS-CoV 2 sehingga skrining rutin menjadi hal yang sangat perlu dilakukan pada pegawai laboratorium. Kegiatan dilaksanakan dengan mengidentifikasi pegawai laboratorium RSI Surabaya Jemursari untuk kemudian dilakukan anamnesis dan pemeriksaan fisik. Kemudian dilakukan pengambilan swab nasofaring untuk pemeriksaan antigen serta pengambilan da

APA, Harvard, Vancouver, ISO, and other styles

11

Liang, Jihao, Yang Zheng, Xin Tong, Naixue Yang, and Shaoxing Dai. "In Silico Identification of Anti-SARS-CoV-2 Medicinal Plants Using Cheminformatics and Machine Learning." Molecules 28, no. 1 (2022): 208. http://dx.doi.org/10.3390/molecules28010208.

Full text

Abstract:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19, is spreading rapidly and has caused hundreds of millions of infections and millions of deaths worldwide. Due to the lack of specific vaccines and effective treatments for COVID-19, there is an urgent need to identify effective drugs. Traditional Chinese medicine (TCM) is a valuable resource for identifying novel anti-SARS-CoV-2 drugs based on the important contribution of TCM and its potential benefits in COVID-19 treatment. Herein, we aimed to discover novel anti-SARS-CoV-2 compounds and medicina

APA, Harvard, Vancouver, ISO, and other styles

12

Naully, Patricia Gita, and Perdina Nursidika. "Hasil Positif Palsu dan Negatif Palsu pada Pemeriksaan Cepat Antibodi SARS CoV-2." Jurnal Kesehatan Vokasional 6, no. 2 (2021): 81. http://dx.doi.org/10.22146/jkesvo.62775.

Full text

Abstract:

Latar Belakang: Salah satu cara yang dilakukan Indonesia untuk mengendalikan dan mencegah penularan SARS CoV-2 sebagai penyebab COVID-19 adalah dengan menyediakan kit pemeriksaan cepat anti-SARS CoV-2. Metode pemeriksaan tersebut dapat mengatasi keterbatasan tenaga ahli dan alat laboratorium di Indonesia. Tujuan: Menentukan hasil pemeriksaan cepat anti-SARS CoV-2 pada masyarakat di Kecamatan Cimahi Tengah.Metode: Sebanyak 50 orang diambil sebagai sampel penelitian dengan menggunakan teknik quota sampling. Pemeriksaan cepat anti-SARS CoV-2 dilakukan dengan menggunakan imunokromatografi merek Lu

APA, Harvard, Vancouver, ISO, and other styles

13

Rungrojcharoenkit, Kamonthip, Rungarun Suthangkornkul, Darunee Utennam, et al. "Standardization of in-house anti-IgG and IgA ELISAs for the detection of COVID-19." PLOS ONE 18, no. 6 (2023): e0287107. http://dx.doi.org/10.1371/journal.pone.0287107.

Full text

Abstract:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). RT-PCR detection of viral RNA represents the gold standard method for diagnosis of COVID-19. However, multiple diagnostic tests are needed for acute disease diagnosis and assessing immunity during the COVID-19 outbreak. Here, we developed in-house anti-RBD IgG and IgA enzyme-linked immunosorbent assays (ELISAs) using a well-defined serum sample panel for screening and identification of human SARS-CoV-2 infection. We found that our in-house anti-SARS-CoV-2 IgG ELISA displa

APA, Harvard, Vancouver, ISO, and other styles

14

Adeniyi, Oladele Vincent, Oyewole Christopher Durojaiye, and Charity Masilela. "Persistence of SARS-CoV-2 IgG Antibody Response among South African Adults: A Prospective Cohort Study." Vaccines 11, no. 6 (2023): 1068. http://dx.doi.org/10.3390/vaccines11061068.

Full text

Abstract:

This study assesses the durability of severe acute respiratory coronavirus-2 (SARS-CoV-2) anti-nucleocapsid (anti-N) immunoglobulin G (IgG) after infection and examines its association with established risk factors among South African healthcare workers (HCWs). Blood samples were obtained from 390 HCWs with diagnosis of coronavirus disease 2019 (COVID-19) for assay of the SARS-CoV-2 anti-N IgG at two time points (Phase 1 and 2) between November 2020 and February 2021. Out of 390 HCWs with a COVID-19 diagnosis, 267 (68.5%) had detectable SARS-CoV-2 anti-N IgG antibodies at the end of Phase I. T

APA, Harvard, Vancouver, ISO, and other styles

15

Vicidomini, Caterina, and Giovanni N. Roviello. "Potential Anti-SARS-CoV-2 Molecular Strategies." Molecules 28, no. 5 (2023): 2118. http://dx.doi.org/10.3390/molecules28052118.

Full text

Abstract:

Finding effective antiviral molecular strategies was a main concern in the scientific community when the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 as an easily transmissible and potentially deadly β-coronavirus able to cause the coronavirus disease 19 (COVID-19), which famously led to one of the most worrying pandemics in recent times. Other members of this zoonotic pathogenic family were already known before 2019, but apart from the SARS-CoV, which was responsible of severe acute respiratory syndrome (SARS) pandemic in 2002/2003, and Middle East r

APA, Harvard, Vancouver, ISO, and other styles

16

Staats, Léonie A. N., Hella Pfeiffer, Jasmin Knopf, et al. "IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients." Cells 9, no. 12 (2020): 2676. http://dx.doi.org/10.3390/cells9122676.

Full text

Abstract:

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to an adaptive immune response in the host and the formation of anti-SARS-CoV-2 specific antibodies. While IgG responses against SARS-CoV-2 have been characterized quite well, less is known about IgA. IgA2 activates immune cells and induces inflammation and neutrophil extracellular trap (NET) formation which may contribute to organ injury and fatal outcome in SARS-CoV-2-infected patients. SARS-CoV-2 spike protein specific antibody levels were measured in plasma samples of 15 noninfected controls and 82 SARS-CoV-2

APA, Harvard, Vancouver, ISO, and other styles

17

El-Khoury, Joe M., Wade L. Schulz, and Thomas J. S. Durant. "Longitudinal Assessment of SARS-CoV-2 Antinucleocapsid and Antispike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection." Journal of Applied Laboratory Medicine 6, no. 4 (2021): 1005–11. http://dx.doi.org/10.1093/jalm/jfab030.

Full text

Abstract:

Abstract Background SARS-CoV-2 serologic assays are becoming increasingly available and may serve as a diagnostic aid in a multitude of settings relating to past infection status. However, there is limited literature detailing the longitudinal performance of EUA-cleared serologic assays in US populations, particularly in cohorts with a remote history of PCR-confirmed SARS-CoV-2 infection (e.g., &gt;2 months). Methods We evaluated the diagnostic sensitivities and specificities of the Elecsys® Anti-SARS-CoV-2 (anti-N) and Elecsys Anti-SARS-CoV-2 S (anti-S1-RBD) assays, using 174 residual cli

APA, Harvard, Vancouver, ISO, and other styles

18

Annamaria, Petrungaro, Quartarone Eugenia, and Sciarrone Paolo. "Anti-SARS-CoV-2 hyperimmune plasma workflow." Transfusion and Apheresis Science 59, no. 5 (2020): 102850. http://dx.doi.org/10.1016/j.transci.2020.102850.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Jizzini, Mazen, Mohsin Shah, and Kehua Zhou. "SARS-CoV-2 and Anti-Cardiolipin Antibodies." Clinical Medicine Insights: Case Reports 13 (January 2020): 117954762098038. http://dx.doi.org/10.1177/1179547620980381.

Full text

Abstract:

The current COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to distinct diagnostic and management challenges for front-line healthcare workers. The risk of excessive coagulation activation leading to a cascade of thrombotic events in critically ill patients with SARS-CoV-2 is now well reported. We discuss a recent case of COVID-19 with concurrent acute pulmonary embolism and a positive cardiolipin antibody (IgM). The presence of antiphospholipid antibodies is key to diagnosing antiphospholipid syndrome (APS). However, their presence can be t

APA, Harvard, Vancouver, ISO, and other styles

20

Dalinkeviciene, Egle, Brigita Gradauskiene, Sandra Sakalauskaite, et al. "Immune Response after Anti-SARS-CoV-2 mRNA Vaccination in Relation to Cellular Immunity, Vitamin D and Comorbidities in Hemodialysis Patients." Microorganisms 12, no. 5 (2024): 861. http://dx.doi.org/10.3390/microorganisms12050861.

Full text

Abstract:

In the global threat of SARS-CoV-2, individuals undergoing maintenance dialysis represent a vulnerable population with an increased risk of severe COVID-19 outcomes. Therefore, immunization against SARS-CoV-2 is an essential component of healthcare strategy for these patients. Existing data indicate that they tend to exhibit a reduced immune response to vaccines compared to the general population. Our study aimed to assess both humoral and cellular immune responses following two doses of an anti-SARS-CoV-2 mRNA vaccine, an ability to maintain adequate antibody titers over time, and potential r

APA, Harvard, Vancouver, ISO, and other styles

21

Taha, Ahmed E., Abdulrahman A. Alduraywish, Abdulrahman H. Almaeen, et al. "High Seroprevalence of Anti-SARS-CoV-2 IgM/IgG among Inhabitants of Sakaka City, Aljouf, Saudi Arabia." Vaccines 11, no. 1 (2022): 26. http://dx.doi.org/10.3390/vaccines11010026.

Full text

Abstract:

(1) Backgrounds and Objectives: The global battle to contain the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is still ongoing. This cross-sectional study aimed to detect the seroprevalence of anti-SARS-CoV-2 IgM/IgG among previously symptomatic/asymptomatic and vaccinated/unvaccinated inhabitants of Sakaka City, Aljouf, Saudi Arabia. (2) Methods: Blood samples of 400 participants were tested for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immuno-chromatography lateral flow immunoassay cards. (3) Results: The prevalence of anti-SARS-CoV-2 IgM and IgG positivity

APA, Harvard, Vancouver, ISO, and other styles

22

Ghandili, Susanne, Martin Schönlein, Marc Lütgehetmann, et al. "Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment." Cancers 13, no. 15 (2021): 3800. http://dx.doi.org/10.3390/cancers13153800.

Full text

Abstract:

Few data are available regarding the efficacy of anti-SARS-CoV-2 vaccines in patients with hematological malignancies, and particular, plasma cell neoplasia. This ongoing single-center study aimed to describe the level of post-vaccination anti-SARS-CoV-2-antibodies depending on B lymphocyte count, current therapy, and remission status of patients with multiple myeloma and related plasma cell dyscrasia, after the first dose of anti-SARS-CoV-2 vaccination. The 82 patients included in this study received SARS-CoV-2 vaccines (including mRNA- and vector-based vaccines) as a routine measure. After t

APA, Harvard, Vancouver, ISO, and other styles

23

Abd-Alla, Howaida I., Omnia Kutkat, Heba-tollah M. Sweelam, et al. "Investigating the Potential Anti-SARS-CoV-2 and Anti-MERS-CoV Activities of Yellow Necklacepod among Three Selected Medicinal Plants: Extraction, Isolation, Identification, In Vitro, Modes of Action, and Molecular Docking Studies." Metabolites 12, no. 11 (2022): 1109. http://dx.doi.org/10.3390/metabo12111109.

Full text

Abstract:

The anti-MERS-CoV activities of three medicinal plants (Azadirachta indica, Artemisia judaica, and Sophora tomentosa) were evaluated. The highest viral inhibition percentage (96%) was recorded for S. tomentosa. Moreover, the mode of action for both S. tomentosa and A. judaica showed 99.5% and 92% inhibition, respectively, with virucidal as the main mode of action. Furthermore, the anti-MERS-CoV and anti-SARS-CoV-2 activities of S. tomentosa were measured. Notably, the anti-SARS-CoV-2 activity of S. tomentosa was very high (100%) and anti-MERS-CoV inhibition was slightly lower (96%). Therefore,

APA, Harvard, Vancouver, ISO, and other styles

24

Eberhardt, Kirsten Alexandra, Felix Dewald, Eva Heger, et al. "Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG." Microorganisms 9, no. 4 (2021): 733. http://dx.doi.org/10.3390/microorganisms9040733.

Full text

Abstract:

Background: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. Methods: Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON® SARS-C

APA, Harvard, Vancouver, ISO, and other styles

25

Bichara, Carlos David Araújo, Maria Alice Freitas Queiroz, Ednelza da Silva Graça Amoras, et al. "Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil." Vaccines 9, no. 10 (2021): 1169. http://dx.doi.org/10.3390/vaccines9101169.

Full text

Abstract:

The present study evaluated the frequency of seropositivity for anti-SARS-CoV-2 (S1 and S2) total antibodies and anti-SARS-CoV-2 (receptor binding domain-RBD-S1) neutralizing antibodies in individuals vaccinated with the immunizing agent Coronavac. This was a cross-sectional study involving 358 individuals divided into two groups. Group 1 consisted of 205 volunteers who were tested for anti-SARS-CoV-2 total antibodies; group 2 consisted of 153 individuals tested for the presence of anti-SARS-CoV-2 neutralizing antibodies. Seropositivity was greater than 70% in both groups, although 17.6% and 2

APA, Harvard, Vancouver, ISO, and other styles

26

Bong, Ji-Hong, Tae-Hun Kim, Jaeyong Jung, et al. "Competitive Immunoassay of SARS-CoV-2 Using Pig Sera-Derived Anti-SARS-CoV-2 Antibodies." BioChip Journal 15, no. 1 (2021): 100–108. http://dx.doi.org/10.1007/s13206-021-00011-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ciepłucha, Hubert Dawid, Małgorzata Zalewska, Krzysztof Kujawa, and Bartosz Szetela. "Prevalence of Anti-SARS-CoV-2 Antibodies in HIV-Positive Patients in Wroclaw, Poland—Unexpected Difference between First and Second Wave." COVID 2, no. 12 (2022): 1748–57. http://dx.doi.org/10.3390/covid2120125.

Full text

Abstract:

Background: The presence and level of anti-SARS-CoV-2 antibodies in PLWH from the Lower Silesia region in Poland. Material and Methods: A total of 216 serum samples of both sexes, aged 21–77, and treated with TDF or TAF together with FTC and INSTI at two points of time. Anyone who did not experience COVID-19 symptoms. Samples were checked for the presence and levels of anti-SARS-CoV-2 antibodies regarding CD4 + T and CD8 + T cells counts, the ratio of these cells, age, sex, VL, and type of tenofovir used. Results: The average level and prevalence of anti-SARS-CoV-2 antibodies during the first

APA, Harvard, Vancouver, ISO, and other styles

28

Riccomi, A., C. M. Trombetta, M. Dorrucci, et al. "Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination." Vaccines 12, no. 4 (2024): 425. http://dx.doi.org/10.3390/vaccines12040425.

Full text

Abstract:

A number of studies have suggested that influenza vaccination can provide protection against COVID-19, but the underlying mechanisms that could explain this association are still unclear. In this study, the effect of the 2021/2022 seasonal influenza vaccination on the immune response to the booster dose of anti-SARS-CoV-2 vaccination was evaluated in a cohort of healthy individuals. A total of 113 participants were enrolled, 74 of whom had no prior COVID-19 diagnosis or significant comorbidities were considered for the analysis. Participants received the anti-influenza tetravalent vaccine and

APA, Harvard, Vancouver, ISO, and other styles

29

Salvagno, Gian Luca, and Giuseppe Lippi. "Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization." Vaccines 10, no. 6 (2022): 890. http://dx.doi.org/10.3390/vaccines10060890.

Full text

Abstract:

Objective: In this work we monitored both total and IgG anti-SARS-CoV-2 antibodies responses after BNT162b2 vaccine booster immunization in a cohort of ostensibly healthy healthcare workers. Methods: The study population consisted of 266 subjects (median age, 46 years and interquartile range (IQR), 35–52 years; 168 females) undergoing homologous 30-µg BNT162b2 booster administration. Serum samples were collected immediately before the booster dose and 1 month after. Results: The concentration of anti-SARS-CoV-2 RBD total antibodies and anti-SARS-CoV-2 spike trimeric IgG increased by 31 (IQR, 1

APA, Harvard, Vancouver, ISO, and other styles

30

Mubayinah. "ANALYSIS OF ANTIBODY RESPONSE TO SARS-COV-2 VACCINATION AND ITS RELATION WITH AGE IN PATIENTS AT PRODIA ARTERY." Muhammadiyah International Public Health and Medicine Proceeding 2, no. 1 (2022): 273–77. http://dx.doi.org/10.61811/miphmp.v1i2.244.

Full text

Abstract:

One of the efforts to overcome Covid-19 is the vaccination program. Anti-SARS CoV-2 is an antibody against Sars-CoV-2 formed due to previous exposure to Covid-19 infection or due to the administration of the Covid-19 vaccine. This study aims to determine the average number of Anti-Sars-CoV-2 respondents vaccinated against Covid 19 and the relationship between age and the number of Anti-Sars-CoV-2. This research is a quantitative study with an observation method with a cross-sectional approach which means looking for a relationship between the independent variable and the dependent variable, an

APA, Harvard, Vancouver, ISO, and other styles

31

Burns, Madeleine D., Cordelia Muir, Caroline Atyeo, et al. "Relationship between Anti-Spike Antibodies and Risk of SARS-CoV-2 Infection in Infants Born to COVID-19 Vaccinated Mothers." Vaccines 10, no. 10 (2022): 1696. http://dx.doi.org/10.3390/vaccines10101696.

Full text

Abstract:

The goal of this study was to investigate the relationship between anti-SARS-CoV-2-Spike IgG titers passively transferred to the fetus from maternal vaccination during pregnancy and timing of infant SARS-CoV-2 infection. Pregnant, vaccinated individuals (n = 105) and their infants (n = 107) were enrolled in a prospective cohort study from July 2021 to June 2022, linking infant anti-Spike IgG titer at birth to risk of SARS-CoV-2 infection in the first fifteen months of life. Cord blood sera were collected at delivery and infant sera were collected at two and six months of age. Anti-SARS-CoV-2-S

APA, Harvard, Vancouver, ISO, and other styles

32

Santoro, Annapaola, Andrea Capri, Daniele Petrone, et al. "SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel." Biomedicines 11, no. 5 (2023): 1247. http://dx.doi.org/10.3390/biomedicines11051247.

Full text

Abstract:

Background: Vaccine-induced SARS-CoV-2-anti-spike antibody (anti-S/RBD) titers are often used as a marker of immune protection and to anticipate the risk of breakthrough infections, although no clear cut-off is available. We describe the incidence of SARS-CoV-2 vaccine breakthrough infections in COVID-19-free personnel of our hospital, according to B- and T-cell immune response elicited one month after mRNA third dose vaccination. Methods: The study included 487 individuals for whom data on anti-S/RBD were available. Neutralizing antibody titers (nAbsT) against the ancestral Whuan SARS-CoV-2,

APA, Harvard, Vancouver, ISO, and other styles

33

Quee, Franke A., Boris M. Hogema, Michel Molier, Ed Slot, Katja van den Hurk, and Hans L. Zaaijer. "The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance." PLOS ONE 19, no. 7 (2024): e0305613. http://dx.doi.org/10.1371/journal.pone.0305613.

Full text

Abstract:

Introduction Serological surveillance is useful for assessing SARS-CoV-2 immunity in populations. To effectively study the presence and persistence of antibodies, it is necessary to distinguish between persons with past infection, and persons who only received vaccination. Knowledge of the duration of antibody persistence is essential for correct interpretation of surveillance results. Methods Starting in April 2020, waning of SARS-CoV-2 antibodies was studied in a longitudinal cohort study of 495 SARS-CoV-2 antibody-positive Dutch blood donors, not pre-selected by PCR testing or disease sever

APA, Harvard, Vancouver, ISO, and other styles

34

Artauli, Sari, Silvia Tri Widyaningtyas, and Fera Ibrahim. "Konstruksi Plasmid Pengekspresi Antigen Rekombinan Spike dan Nukleokapsid SARS-CoV-2 untuk Deteksi Antibodi Anti-SARS-CoV-2." Jurnal Biotek Medisiana Indonesia 10, no. 2 (2021): 87–96. http://dx.doi.org/10.22435/jbmi.v10i2.5820.

Full text

Abstract:

ABSTRACT Covid-19 infection is still a health problem in Indonesia and even throughout the globe. To control Covid-19, efforts are made for each country to conduct research to develop raw materials that can be used for anti-SARS-CoV-2 detection in serological diagnostics. This study aimed to construct recombinant plasmids expressing SARS-CoV-2 antigen so that it be used in the production of raw materials in developing the SARS-CoV-2 serological test. The genes coding spike and nucleocapsid recombinant antigens cloned in pUC57 were subcloned into the pQE80L expression vector to produce pQ

APA, Harvard, Vancouver, ISO, and other styles

35

Bagno, Flávia F., Luis A. F. Andrade, Sarah A. R. Sérgio, et al. "Previous Infection with SARS-CoV-2 Correlates with Increased Protective Humoral Responses after a Single Dose of an Inactivated COVID-19 Vaccine." Viruses 14, no. 3 (2022): 510. http://dx.doi.org/10.3390/v14030510.

Full text

Abstract:

Previous studies have indicated that antibody responses can be robustly induced after the vaccination in individuals previously infected by SARS-CoV-2. To evaluate anti-SARS-CoV-2 humoral responses in vaccinated individuals with or without a previous history of COVID-19, we compared levels of anti-SARS-CoV-2 antibodies in the sera from 21 vaccinees, including COVID-19-recovered or -naïve individuals in different times, before and after immunization with an inactivated COVID-19 vaccine. Anti-SARS-CoV-2-specific antibodies elicited after COVID-19 and/or immunization with an inactivated vaccine w

APA, Harvard, Vancouver, ISO, and other styles

36

Schwarz, Tatjana, Carolin Otto, Terry C. Jones, et al. "Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis." Multiple Sclerosis Journal, May 14, 2022, 135245852210944. http://dx.doi.org/10.1177/13524585221094478.

Full text

Abstract:

Background: Optimal management of anti-CD20-treated patients with multiple sclerosis (pwMS) is an important clinical task during the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Objectives: To characterize humoral and cellular immune responses to SARS-CoV-2 vaccinations/infections in a longitudinal cohort of anti-CD20 treated ( n = 175) and anti-CD20 therapy-naïve ( n = 41) pwMS. Methods: Anti-SARS-CoV-2 spike protein immunoglobulin G (IgG) and IgA, virus neutralizing capacity, IgG avidity and SARS-CoV-2-specific T cells were determined. Results: Following two

APA, Harvard, Vancouver, ISO, and other styles

37

"Convalescent-anti-sars-cov-2-plasma." Reactions Weekly 1852, no. 1 (2021): 141. http://dx.doi.org/10.1007/s40278-021-94594-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1862, no. 1 (2021): 152. http://dx.doi.org/10.1007/s40278-021-98270-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Convalescent-anti-SARS-COV-2-plasma." Reactions Weekly 1915, no. 1 (2022): 147. http://dx.doi.org/10.1007/s40278-022-19176-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1904, no. 1 (2022): 159. http://dx.doi.org/10.1007/s40278-022-14091-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1874, no. 1 (2021): 79. http://dx.doi.org/10.1007/s40278-021-02736-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1880, no. 1 (2021): 128. http://dx.doi.org/10.1007/s40278-021-04962-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Convalescent-anti-sars-cov-2-plasma." Reactions Weekly 1878, no. 1 (2021): 157. http://dx.doi.org/10.1007/s40278-021-04127-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1872, no. 1 (2021): 139. http://dx.doi.org/10.1007/s40278-021-02065-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1865, no. 1 (2021): 153. http://dx.doi.org/10.1007/s40278-021-99441-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Convalescent-anti-SARS-COV-2-plasma." Reactions Weekly 1869, no. 1 (2021): 114. http://dx.doi.org/10.1007/s40278-021-00979-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Convalescent-anti-sars-cov-2-plasma." Reactions Weekly 1894, no. 1 (2022): 116. http://dx.doi.org/10.1007/s40278-022-10229-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Convalescent-anti-sars-cov-2-plasma." Reactions Weekly 1887, no. 1 (2022): 222. http://dx.doi.org/10.1007/s40278-022-07887-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1887, no. 1 (2022): 221. http://dx.doi.org/10.1007/s40278-022-07886-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Convalescent-anti-SARS-CoV-2-plasma." Reactions Weekly 1887, no. 1 (2022): 220. http://dx.doi.org/10.1007/s40278-022-07885-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!